Literature DB >> 27040884

WITHDRAWN: Diuretics for heart failure.

Rajaa F Faris1, Marcus Flather, Henry Purcell, Philip A Poole-Wilson, Andrew J S Coats.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27040884      PMCID： PMC6413766          DOI： 10.1002/14651858.CD003838.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


× No keyword cloud information.
  73 in total

1.  Contracted plasma and blood volume in chronic heart failure.

Authors:  M S Feigenbaum; M A Welsch; M Mitchell; K Vincent; R W Braith; C J Pepine
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

2.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy.

Authors:  E Steiness; K H Olesen
Journal:  Br Heart J       Date:  1976-02

5.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors:  C A Farquharson; A D Struthers
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

6.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 7.  The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.

Authors:  D J van Veldhuisen; P A Poole-Wilson
Journal:  Int J Cardiol       Date:  2001-08       Impact factor: 4.164

8.  Effect of carvedilol on survival in severe chronic heart failure.

Authors:  M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

9.  Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials.

Authors:  R Faris; M Flather; H Purcell; M Henein; P Poole-Wilson; A Coats
Journal:  Int J Cardiol       Date:  2002-02       Impact factor: 4.164

10.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272
View more
  2 in total

Review 1.  Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance.

Authors:  Evan C Ray
Journal:  Curr Opin Pharmacol       Date:  2020-07-15       Impact factor: 5.547

Review 2.  Hypertensive Heart Failure in Asia.

Authors:  Helsi Rismiati; Hae-Young Lee
Journal:  Pulse (Basel)       Date:  2021-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.